anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a lipid-lowering and liver-protecting herbal tea which is mainly composed of the eight components of: licorice, honeysuckle flower, chrysanthemum, cassia seed, hawthorn fruit, Mongolian milkvetch root, oriental waterplantain tuber, and Chinese magnoliavine fruit. The formulas for the herbal tea can be divided into a common formula and a sugar-free formula. According to the common formula, a sucrose sweetening agent is added. According to the sugar-free formula, sugar stevia leaves are added to be decocted together, or sucralose, aspartame, or xylitol is added. All the components adopted by the invention are natural raw materials. A total flavonoid content of the herbal tea is high. The tea has substantial functions such as lipid lowering and liver protecting. The herbal tea also has functions of blood pressure reducing, cholesterol reducing, cardiovascular disease preventing, and the like.
BACKGROUND AND AIMS: To investigate if treatment with non-pooled, multidonor faecal microbiota transplantation [FMT] for 4 weeks was superior to placebo to induce clinical remission in patients with chronic pouchitis.
METHODS: The study was a randomised, double-blinded, placebo-controlled study with a 4-week intervention period and 12-month follow-up. Eligible patients with chronic pouchitis were recruited from five Danish hospitals. Participants were randomised to non-pooled, multidonor FMT derived from four faecal donors, or placebo. Treatment was delivered daily by enema for 2 weeks, followed by every second day for 2 weeks. Disease severity was accessed at inclusion and 30-day follow-up, using the Pouchitis Disease Activity Index [PDAI]; PDAI <7 was considered equivalent to clinical remission. Faecal samples from participants and donors were analysed by shotgun metagenomic sequencing.
RESULTS: Inclusion was stopped after inclusion of 30 participants who were randomised 1:1 for treatment with FMT or placebo. There was no difference in participants achieving clinical remission between the two groups at 30-day follow-up, relative risk 1.0 (95% CI [0.55; 1.81]). Treatment with FMT resulted in a clinically relevant increase in adverse events compared with placebo, incidence rate ratio 1.67 (95% CI [1.10; 2.52]); no serious adverse events within either group. Faecal microbiota transplantation statistically significantly increased the similarity of participant faecal microbiome to the faecal donor microbiome at 30-day follow-up [p = 0.01], which was not seen after placebo.
CONCLUSIONS: Non-pooled, multidonor FMT was comparable to placebo in inducing clinical remission in patients with chronic pouchitis, but showed a clinically relevant increase in adverse events compared with placebo. ClincialTrials.gov number, NCT04100291.
Blind adults display language-specificity in their packaging and ordering of events in speech. These differences affect the representation of events in co-speech gesture-gesturing with speech-but not in silent gesture-gesturing without speech. Here we examine when in development blind children begin to show adult-like patterns in co-speech and silent gesture. We studied speech and gestures produced by 30 blind and 30 sighted children learning Turkish, equally divided into 3 age groups: 5-6, 7-8, 9-10 years. The children were asked to describe three-dimensional spatial event scenes (e.g., running out of a house) first with speech, and then without speech using only their hands. We focused on physical motion events, which, in blind adults, elicit cross-linguistic differences in speech and co-speech gesture, but cross-linguistic similarities in silent gesture. Our results showed an effect of language on gesture when it was accompanied by speech (co-speech gesture), but not when it was used without speech (silent gesture) across both blind and sighted learners. The language-specific co-speech gesture pattern for both packaging and ordering semantic elements was present at the earliest ages we tested the blind and sighted children. The silent gesture pattern appeared later for blind children than sighted children for both packaging and ordering. Our findings highlight gesture as a robust and integral aspect of the language acquisition process at the early ages and provide insight into when language does and does not have an effect on gesture, even in blind children who lack visual access to gesture. RESEARCH HIGHLIGHTS: Gestures, when produced with speech (i.e., co-speech gesture), follow language-specific patterns in event representation in both blind and sighted children. Gestures, when produced without speech (i.e., silent gesture), do not follow the language-specific patterns in event representation in both blind and sighted children. Language-specific patterns in speech and co-speech gestures are observable at the same time in blind and sighted children. The cross-linguistic similarities in silent gestures begin slightly later in blind children than in sighted children.
PROBLEM TO BE SOLVED: To obtain the subject diagnostic agent capable of safely and simply analyzing hepatic conditions, irrespective of conditions of the examinee, by including an amino acid marked with<13> C for the carbon atom at the specific site, selected from the group consisting of a polar amino acid, heterocyclic amino acid and branched amino acid. SOLUTION: This diagnostic agent is obtained by including at least one type of marker amino acid with<13> C for the carbon atom at the specific site, selected from the group consisting of a polar amino acid (e.g. arginine, glutamic acid or the like), heterocyclic amino acid (e.g. tryptophan, proline or the like) and branched amino acid (leucine, isoleucine or the like), preferably at normally 1 to 100 wt.% based on the whole agent composition. Hepatic conditions of an examinee to which this agent is given once or continuously can be accurately diagnosed by following rate of increase in CO2 marked with<13> C in his expiration. It is preferable to give this agent to an adult examinee at a dose of 1 to 1000 mg/kg of body weight.
INTRODUCTION: Duodenal-jejunal bypass (DJB) is an experimental procedure in metabolic surgery that does not have a restrictive component. Changes in bile acid (BA) dynamics and intestinal microbiota are possibly related to metabolic improvement after DJB. Our previous studies involving obese diabetic rats showed the crucial role of the biliopancreatic limb (BPL) in metabolic improvement after DJB caused by BA reabsorption. We established a new DJB procedure to prevent bile from flowing into the BPL and aimed to elucidate the importance of bile in the BPL after DJB.
METHODS: Otsuka Long-Evans Tokushima Fatty rats with diabetes were divided into three groups: two DJB groups and a sham group (n = 11). Duodenal-jejunal anastomosis was performed proximal to the papilla of Vater in the DJB group (n = 11). However, the DJB-D group (n = 11) underwent a new procedure with duodenal-jejunal anastomosis distal to the papilla of Vater for preventing bile flow into the BPL.
RESULTS: Glucose metabolism improved and weight gain was suppressed in the DJB group, but not in the DJB-D and sham groups. Serum BA level and conjugated BA concentration were elevated in the DJB group. The gut microbiota was altered only in the DJB group; the abundance of Firmicutes and Bacteroidetes decreased and that of Actinobacteria increased. However, the DJB-D group exhibited no apparent change in the gut microbiota, similar to the sham group.
CONCLUSION: BAs are essential in the BPL for metabolic improvement after DJB; they can improve the gut microbiota in these processes.
PURPOSE: A Rhus chinensis Mill. salt with an antiaging effect and a method for preparing the same are provided to enhance phenol compound content, iron reduction, and anti-inflammation, and to suppress elastase. CONSTITUTION: A pharmaceutical composition for antiaging contains a Rhus chinensis Mill. salt containing a Rhus chinensis Mill. extract and a salt as an active ingredient. A pharmaceutical composition for anti-inflammation contains the Rhus chinensis Mill. salt as an active ingredient. A pharmaceutical composition for enhancing immunity contains the Rhus chinensis Mill. salt as an active ingredient. The pharmaceutical compositions contain 10-30 wt% of the Rhus chinensis Mill. extract.
In this projects the investigators aim to re-establish a gut balance of intestinal microbiota through Standardized Fecal Microbiota Transplantation for IBD (UC and CD). We have established a standardized isolation, store, and transport steps of fecal bacteria from donated fresh stool in the laboratory. Then the bacteria will be transplanted to mid-gut by capsule. Patients in this study will be assigned to receive standardized FMT three times or not and would be followed up for at least 1 year. The clinical symptoms, sign, blood tests, endoscopy and questionnaire will be used to assess the efficiency, durability and safety of Standardized FMT at the start and end of the projects. At last, we will use 16S-rDNA to estimate the change of intestinal microbiota.
In 2019, nearly one third of cancers diagnosed in the United States were breast cancers. Per the Plastic Surgery procedural statistics from the American Society of Plastic Surgery database, that same year approximately 107,000 patients decided to pursue either alloplastic (ex. Tissue expander or implant based) or autologous (ex. Transverse Rectus Abdominis Muscle (TRAM), Deep Inferior Epigastric Perforator (DIEP) flaps) breast reconstruction, an increase of 5% from 2018. Over the past few decades, as surgical techniques have continued to improve, postoperative concerns have transitioned towards the patient's aesthetic outcome and satisfaction. While the appropriate size, shape, and symmetry of the breast are crucial goals to achieve, another issue facing patients is that without sensation the reconstructed breast does not feel like their own. In most patients there is diminished, if not absent, sensation in the reconstructed breast. The lack of sensation can not only put patients at risk of injury, but also can impact their lives sexually and socially.

The goal of this randomized, double-blinded study is to prospectively evaluate the impact of neurotization on breast-specific quality of life in patients who have undergone autologous reconstruction. Secondary objectives are to also look at additional health-related quality of life outcomes using validated surveys (e.g. PROMIS and NIH Toolbox). These NIH-funded surveys will be analyzed to assess factors important to surgical impact on physical function, mental function, social function, pain, and sexual function. Finally, investigators will objectively measure differences in sensation. Investigators hypothesize that breast neurotization will improve both breast- and health-related patient quality of life outcomes as well as objective sensation. The duration of this study is expected to be approximately 48 months in order to recruit an appropriate number of patients and have adequate postoperative follow up.
Despite long-term outcomes of kidney and liver transplantation significantly improved in the last decades, high morbidity and mortality is still an issue at short term after transplantation. Specifically, occurrence of delayed graft function (DGF) and early acute rejection (AR) may cause multi-organ failure or graft failure, admission to intensive care unit, prolonged hospitalization and high-dosage immunosuppressive therapy which might expose patients to several further complications such as infections, neoplasm, and metabolic disease. Consequently, solid organ transplant recipients represent a very frail population at high risk of complications. Therefore, development of new biomarkers for the prevention and early diagnosis of the major post-transplant complications influencing the morbidity and mortality of solid organ transplant recipients are needed. Adrenomedullin (ADM) is a 52-amino acid peptide with a variety of physiologic functions such as immunemodulating activity, direct bactericidal activity, maintenance of renal homeostasis, and vasodilatory activity. Recent study has shown that midregional proADM (MR-proADM) is co-synthesized with ADM in equimolar amounts and has the advantages of a longer half-life, lack of bioactivity and lack of protein binding. MR-proADM has been recognized as a prognostic marker, stratifying the mortality risk in patients with sepsis in intensive care units. Moreover, recently MD-proADM has been also associated with risk of specific organ failure such as acute kidney injury, acute liver damage, acute respiratory distress syndrome and acute cardiac injury. Literature results suggest that recovery of graft function after KT may lead to decrease in plasma MR-proADM level in patients with ESRD, and that plasma MR-proADM level may could increase in the early phases of DGF and AR after KT and LT as a response damage and to the immune activation. The study will allow to evaluate the utility MR-proADM as an early biomarker of DGF and AR in patients undergoing kidney and liver transplantation at our Institution. Also, the study aims to analyze how the value of this biomarker can change in association with post-transplant complication and to create a predicting model by machine cut-off values of references for MR-proADM.
After three injections of thoracic paravertebral block at T2, T4, T6 (a total of 21ml of 0.5% levobupivacaine with 1:200,000 adrenaline) under ultrasound guidance, patients will be put in supine position with ipsilateral arm and elbow flexed. Ultrasound scan will be performed below collarbone region, 5ml of 0.25% levobupivacaine will be injected in the first plane between pectoralis major and minor. Then under direct ultrasound visualization, the remaining 5ml of 0.25% levobupivacaine will be injected between the second plane of pectoralis minor and serratus anterior muscle (a total of 10ml will be given).
In those randomized to radiation arm with receive high dose radiation with Intensity Modulated Radiation Therapy in addition to systemic and concurrent chemotherapy. The gross tumor will comprise the high dose volume. The adjacent areas of suspected microscopic disease will form the low dose volume. When only external radiation is used the aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1. However, if Stage 1 intervention is not effective, half of them will randomized to receive PBO-LLINs plus larval source management (LSM) at Stage 2. LSM will be implemented in selected clusters, including chemical methods by larviciding of semi-permanent and permanent habitats, per the National Malaria Strategic Plan of Kenya. The investigators will use the long-lasting microbial larvicides manufactured by Central Life Sciences. Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet.
No carcinogenic potential was demonstrated in an 18 month study in rats with prazosin hydrochloride at dose levels more than 225 times the usual maximum recommended human dose of 20 mg per day. Prazosin hydrochloride was not mutagenic in in vivo genetic toxicology studies. In a fertility and general reproductive performance study in rats, both males and females, treated with 75 mg/kg (225 times the usual maximum recommended human dose), demonstrated decreased fertility, while those treated with 25 mg/kg (75 times the usual maximum recommended human dose) did not.

  


In chronic studies (one year or more) of prazosin hydrochloride in rats and dogs, testicular changes consisting of atrophy and necrosis occurred at 25 mg/kg/day (75 times the usual maximum recommended human dose). No testicular changes were seen in rats or dogs at 10 mg/kg/day (30 times the usual maximum recommended human dose). In view of the testicular changes observed in animals, 105 patients on long term prazosin hydrochloride therapy were monitored for 17-ketosteroid excretion and no changes indicating a drug effect were observed. In addition, 27 males on prazosin hydrochloride for up to 51 months did not have changes in sperm morphology suggestive of drug effect.
Provided is a skin enhancing agent made of extracts of five or more types of dried medicinal herb plants selected from the group consisting of gallnut, Opuntia ficus-indica, Cayratia japonica, Paederia scandens var. mairei., Angelica tenuissima Nakai, pomegranate, Korean lespedeza, Kalopanax bark, Thuja orientalis, Cnidium monnieri, Houttuynia cordata, Coix lacryma-jobi var. Ma Yuen, noni, and castor bean. According to the present invention, extracts of medicinal herb plants show excellent skin moisturizing, skin whitening, wrinkle treatment, and skin disease alleviation effects; have no toxicity; do not cause safety-related problems such as skin irritation, allergy, etc.; and can be used for all skin types. Accordingly, the extracts can be used as effective components of a cosmetic composition for skin enhancement.
Subjects will receive treatment A and B in following sequence in four treatment periods (one treatment per period): ABBA, where treatment A is 7 doses of FSC (100/50 mcg) delivered via the Ddpi and treatment B is 7 doses of FSC (100/50mcg) delivered via the Rdpi. Subjects will be dosed twice daily for 3 days and once on the fourth day in the morning (a single inhalation of 100/50mcg per dose).
Patients randomized to this arm will receive the composite fish oil lipid, Smoflipid, at standard dosing up to 3 g/kg/day. Patients will be started on a dose of 1 g/kg/day and titrated up to maximum dose. As enteral nutrition is advanced the lipid dose will be weaned per study protocol and dietary recommendations.
Patients with oesophageal motility disorders may present with dysphagia, regurgitation or chest pain. High-resolution manometry (HRM) is the current gold-standard modality for the diagnosis of oesophageal motility disorders. The data from HRM are analysed and interpreted to form a diagnosis based on the Chicago classification. However, the Chicago classification is a work in progress, and a few cases can present with features beyond the scope of the current Chicago classification. We present two such cases with distinctive manometric features of an elevated distal contractile integral and increased integrated relaxation pressure but no intrabolus pressurisation or decreased distal latency. As such, they do not fit into any pattern described in the current Chicago classification V.4.0 and can be best described as overlap motility disorders or mixed motor disorders. Patients with such findings warrant further evaluation and long-term follow-up to understand if they evolve to fit into any disorder currently described in the Chicago classification.
An isolated histamine-like receptor polypeptide comprising the amino acid sequence of SEQ ID No 2 or a variant, or a fragment, of this which is capable of binding histamine or a structurally related molecule. Alternatively the polypeptide may have at least 80% identity to SEQ ID No 2. Methods of screening compounds, in vivo and in vitro, to identify those capable of binding the receptor or modulating its expression are described, as are those substances identified and methods of treatment using them. Antibodies which bind the receptor specifically are also described. The polynucleotide encoding the putative G protein coupled receptor (GPCR) protein is also described which may be used to express the receptor from a vector in a host eukaryotic cell. Methods of gene therapy involving expressing the polynucleotide are described and its use as a probe to determine expression of the receptor gene.
This study will be conducted in two stages. Stage 1 is a 48-week, dose-escalation, open-label evaluation of AR-14034 SR. Two cohorts will be enrolled, for an approximate total of 10 subjects. Subjects in both cohorts will attend visits through Week 48 for assessment of safety and preliminary treatment effects.

Stage 2 is a 56-week (plus extension) double-masked, active comparator, randomized, parallel group evaluation of AR-14034 SR compared with aflibercept. Approximately 130 subjects will be enrolled and randomized 2:2:1 to AR-14034 SR lower dose, AR-14034 SR higher dose, or aflibercept dosed as labelled. Subjects will attend visits through Week 56 for assessment of safety and treatment effects. A 16-week open label extension phase will be conducted thereafter.
Hemolysis-induced acute kidney injury (AKI) is attributed to heme-mediated proximal tubule epithelial cell (PTEC) injury and tubular cast formation due to intratubular protein condensation. Megalin is a multiligand endocytic receptor for proteins, peptides, and drugs in PTECs and mediates the uptake of free hemoglobin and the heme-scavenging protein α1-microglobulin. However, understanding of how megalin is involved in the development of hemolysis-induced AKI remains elusive. Here, we investigated the megalin-related pathogenesis of hemolysis-induced AKI and a therapeutic strategy using cilastatin, a megalin blocker. A phenylhydrazine-induced hemolysis model developed in kidney-specific mosaic megalin knockout (MegKO) mice confirmed megalin-dependent PTEC injury revealed by the co-expression of kidney injury molecule-1 (KIM-1). In the hemolysis model in kidney-specific conditional MegKO mice, the uptake of hemoglobin and α1-microglobulin as well as KIM-1 expression in PTECs was suppressed, but tubular cast formation was augmented, likely due to the nonselective inhibition of protein reabsorption in PTECs. Quartz crystal microbalance analysis revealed that cilastatin suppressed the binding of megalin with hemoglobin and α1-microglobulin. Cilastatin also inhibited the specific uptake of fluorescent hemoglobin by megalin-expressing rat yolk sac tumor-derived L2 cells. In a mouse model of hemolysis-induced AKI, repeated cilastatin administration suppressed PTEC injury by inhibiting the uptake of hemoglobin and α1-microglobulin and also prevented cast formation. Hemopexin, another heme-scavenging protein, was also found to be a novel ligand of megalin, and its binding to megalin and uptake by PTECs in the hemolysis model were suppressed by cilastatin. Mass spectrometry-based semiquantitative analysis of urinary proteins in cilastatin-treated C57BL/6J mice indicated that cilastatin suppressed the reabsorption of a limited number of megalin ligands in PTECs, including α1-microglobulin and hemopexin. Collectively, cilastatin-mediated selective megalin blockade is an effective therapeutic strategy to prevent both heme-mediated PTEC injury and cast formation in hemolysis-induced AKI. © 2024 The Pathological Society of Great Britain and Ireland.